Valuing health-related quality of life: An EQ-5D-5L value set for England

Augustovski, 2016, An EQ-5D-5L value set based on Uruguayan population preferences, Quality of Life Research, 25, 323, 10.1007/s11136-015-1086-4

Bansback, 2012, Using a discrete choice experiment to estimate health state utility values, Journal of Health Economics, 31, 306, 10.1016/j.jhealeco.2011.11.004

Brazier, 2017, Measuring and valuing health benefits for economic evaluation

Brazier, 2002, The estimation of a preference-based measure of health from the SF-36, Journal of Health Economics, 21, 271, 10.1016/S0167-6296(01)00130-8

CADTH [Canadian Agency for Drugs and Technologies in Health], 2006, Guidelines for the economic evaluation of health technologies: Canada [3rd edition]

Cambridgeshire Community Services NHS Trust Quality Account 2013 http://www.nhs.uk/Services/Trusts/Overview/DefaultView.aspx?id=1118 th

Devlin, 2010, Getting the most out of PROMs: Putting health outcomes at the heart of NHS decision making

Devlin, 2017, EQ-5D and the EuroQol group: Past, present, future, Applied Health Economics and Health Policy, 15, 127, 10.1007/s40258-017-0310-5

Devlin, 2013, A comparison of alternative variants of the lead and lag time TTO, Health Economics, 22, 517, 10.1002/hec.2819

Devlin, 2011, A uniform time trade off method for states better and worse than dead: Feasibility study of the ‘lead time’ approach, Health Economics, 20, 348, 10.1002/hec.1596

Dolan, 1997, Modeling valuations for EuroQol health states, Medical Care, 35, 1095, 10.1097/00005650-199711000-00002

Engel, 2016, Exclusion criteria in national health state valuation studies: A systematic review, Medical Decision Making, 36, 798, 10.1177/0272989X15595365

Fayers, 2016, Quality of Life-The assessment, analysis and reporting of patient-reported outcomes

Feng, 2017, New methods for modelling EQ-5D-5L value sets: An application to English data, Health Economics, 27, 23, 10.1002/hec.3560

2016, Health Survey for England 2015

Herdman, 2011, Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Quality of Life Research, 20, 1727, 10.1007/s11136-011-9903-x

Hernández Alava, 2012, Tails from the Peak District: Adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values, Value in Health, 15, 550, 10.1016/j.jval.2011.12.014

Hernandez-Villafuerte, 2014, Do NICE decisions affect decisions in other countries?, Value in Health, 17, A418, 10.1016/j.jval.2014.08.1020

Janssen, 2013, Introducing the composite TTO: A test of feasibility and face validity, European Journal of Health Economics, 14, 5, 10.1007/s10198-013-0503-2

Janssen, 2011, The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus, Diabetes Medicine, 28, 395, 10.1111/j.1464-5491.2010.03136.x

Kim, 2016, The EQ-5D-5L valuation study in Korea, Quality of Life Research, 25, 1845, 10.1007/s11136-015-1205-2

Longworth, 2014, Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: Systematic review, statistical modelling and survey, Health Technology Assessment, 18, 10.3310/hta18090

Mulhern, 2014, Preparatory study for the revaluation of the EQ-5D tariff: Methodology report, Health Technology Assessment, 18, 10.3310/hta18120

Mulhern, 2017, Comparing the UK EQ-5D-3L and the English EQ-5D-5L value sets. OHE Research Paper

2017, Cost-effectiveness in health and medicine

NHS [National Health Service], 2016, GP patient survey: National summary report

NICE [National Institute for Health and Care Excellence], 2013, Guide to the methods of technology appraisal 2013

Office for National Statistics 2011 Census: Digitised boundary data (England and Wales) [computer file] http://edina.ac.uk/ukborders th

Oppe, 2014, A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol, Value in Health, 17, 445, 10.1016/j.jval.2014.04.002

Oppe, 2016, EuroQol protocols for time trade-off valuation of health outcomes, PharmacoEconomics, 34, 993, 10.1007/s40273-016-0404-1

Oppe, 2010, 27th Scientific Plenary Meeting of the EuroQol Group Proceedings, Athens Greece, September 2010

Parkin, 2016, What determines the shape of an EQ-5D index distribution?, Medicinal Decision Making, 36, 941, 10.1177/0272989X16645581

PBAC [Pharmaceutical Benefits Advisory Committee], 2016, Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee

Pickard, 2007, Health utilities using the EQ-5D in studies of cancer, PharmacoEconomics, 25, 365, 10.2165/00019053-200725050-00002

Ramos-Goñi, 2014, Valuation and modeling of EQ-5D-5L health states using a hybrid approach, Medical Care

Richardson, 2014, Encyclopedia of health economics, 341, 10.1016/B978-0-12-375678-7.00505-8

Robinson, 2002, Recognising diversity in public preferences: The use of preference sub-groups in cost-effectiveness analysis. A response to Sculpher and Gafni, Health Economics, 11, 649, 10.1002/hec.735

Robinson, 2006, Exploring challenges to TTO utilities: Valuing states worse than dead, Health Economics, 15, 393, 10.1002/hec.1069

Rowen, 2014, A comparison of methods for converting DCE values onto the Full Health-Dead QALY Scale, Medical Decision Making, 35, 328, 10.1177/0272989X14559542

Ryan, 2008, Using discrete choice experiments to value health and health care, 10.1007/978-1-4020-5753-3

Sculpher, 2001, Recognising diversity in public preferences: The use of preference sub-groups in cost-effectiveness analysis, Health Economics, 10, 314, 10.1002/hec.592

Shah, 2013, One-to-one versus group settings for conducting computer assisted TTO studies: Findings from pilot studies in England and the Netherlands, European Journal of Health Economics, 14, S65, 10.1007/s10198-013-0509-9

Szende, 2007, EQ-5D value sets: Inventory, comparative review and user guide, 10.1007/1-4020-5511-0

Tilling, 2010, TTO valuations of health states worse than dead: A literature review and conceptual framework for systematic analysis, Medical Decision Making, 30, 610, 10.1177/0272989X09357475

Hout, 2012, Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets, Value in Health, 15, 708, 10.1016/j.jval.2012.02.008

Versteegh, 2016, Dutch tariff for the five-level version of EQ-5D, Value in Health, 19, 343, 10.1016/j.jval.2016.01.003

Wailoo, 2010, The incorporation of health benefits in CUA using EQ-5D

Xie, 2015, A checklist for reporting valuation studies of multi-attribute utility-based instruments (CREATE), PharmacoEconomics, 33, 867, 10.1007/s40273-015-0292-9

Xie, 2016, A time trade-off-derived value set of the EQ-5D-5L for Canada, Medical Care, 54, 98, 10.1097/MLR.0000000000000447